Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

Cancer Treatment Reviews

Volumn 36, Issue 7, 2010, Pages 528-538

  Deol, Abhinav ^a   Lum, Lawrence G ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b Hudson Webber Cancer Research Center   (United States)

Author keywords

Donor lymphocyte infusion; Donor lymphocyte transfusion; Graft vs. host disease; Graft vs. leukemia; Hematopoietic stem cell transplantation; Immunotherapy; T cells

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; DASATINIB; IMATINIB; LENALIDOMIDE; NILOTINIB;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASIA; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; REVIEW; TREATMENT RESPONSE; ADVERSE EFFECTS; DONOR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; LYMPHOCYTE TRANSFUSION; RECURRENT DISEASE;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; LYMPHOMA; MULTIPLE MYELOMA; RECURRENCE; TISSUE DONORS;

EID: 77957934068     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.03.004     Document Type: Review

References (110)

1. Thomas E.D., Lochte H.L., Lu W.C., Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957, 257(11):491-496.
2. Reinherz E.L., Geha R., Rappeport J.M., Wilson M., Penta A.C., Hussey R.E., et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci USA 1982, 79(19):6047-6051.
3. Spruce W.E., McMillan R., Miller W., Fox R., Carson D., Schwartz D.B., et al. Transplantation of T-lymphocyte-depleted bone marrow between HLA-mismatched individuals. Transplantation 1983, 36(4):369-372.
4. de Witte T., Raymakers R., Plas A., Koekman E., Wessels H., Haanen C. Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation. Transplantation 1984, 37(2):151-155.
5. Champlin R.E., Mitsuyasu R.T., Gale R.P. Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation. Prog Clin Biol Res 1985, 193:315-325.
6. Trigg M.E., Sondel P.M., Billing R., Finlay J.L., Peterson A., Hong R., et al. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow. J Biol Response Mod 1985, 4(6):602-612.
7. Lowenberg B., Wagemaker G., van Bekkum D.W., Sizoo W., Sintnicolaas K., Hendriks W.D., et al. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986, 1(2):133-140.
8. Patterson J., Prentice H.G., Brenner M.K., Gilmore M., Janossy G., Ivory K., et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986, 63(2):221-230.
9. Gardiner N., Lawler M., O'Riordan J., De'Arce M., McCann S.R. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia. Leukemia 1997, 11(Suppl. 3):512-515.
10. Apperley J.F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y., et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986, 1(1):53-66.
11. Bortin M.M., Horowitz M.M., Rimm A.A. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 1992, 116(6):505-512.
12. Leclair B., Fregeau C.J., Aye M.T., Fourney R.M. DNA typing for bone marrow engraftment follow-up after allogeneic transplant: a comparative study of current technologies. Bone Marrow Transplant 1995, 16(1):43-55.
13. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004, 4(5):371-380.
14. Peggs K.S., Thomson K., Hart D.P., Geary J., Morris E.C., Yong K., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103(4):1548-1556.
15. Bonnet D., Warren E.H., Greenberg P.D., Dick J.E., Riddell S.R. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999, 96(15):8639-8644.
16. Molldrem J.J., Clave E., Jiang Y.Z., Mavroudis D., Raptis A., Hensel N., et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997, 90(7):2529-2534.
17. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76(12):2462-2465.
18. Cullis J.O., Jiang Y.Z., Schwarer A.P., Hughes T.P., Barrett A.J., Goldman J.M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992, 79(5):1379-1381.
19. Ferster A., Bujan W., Mouraux T., Devalck C., Heimann P., Sariban E. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994, 14(2):331-332.
20. Pati A.R., Godder K., Lamb L., Gee A., Henslee-Downey P.J. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995, 15(6):979-981.
21. Sica S., Di Mario A., Salutari P., Rutella S., Chiusolo P., Rumi C., et al. Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16(3):483-485.
22. Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87(6):2195-2204.
23. Lokhorst H.M., Schattenberg A., Cornelissen J.J., Thomas L.L., Verdonck L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90(10):4206-4211.
24. Salama M., Nevill T., Marcellus D., Parker P., Johnson M., Kirk A., et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000, 26(11):1179-1184.
25. Schaap N., Schattenberg A., Bar B., Preijers F., van Kemenade E., de Witte T. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia 2001, 15(9):1339-1346.
26. van der Griend R., Verdonck L.F., Petersen E.J., Veenhuizen P., Bloem A.C., Lokhorst H.M. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23(2):195-197.
27. Verdonck L.F., Petersen E.J., Lokhorst H.M., Nieuwenhuis H.K., Dekker A.W., Tilanus M.G., et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998, 22(11):1057-1063.
28. Drobyski W.R., Roth M.S., Thibodeau S.N., Gottschall J.L. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992, 10(3):301-304.
29. Bar B.M., Schattenberg A., Mensink E.J., Geurts Van Kessel A., Smetsers T.F., Knops G.H., et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993, 11(3):513-519.
30. Drobyski W.R., Keever C.A., Roth M.S., Koethe S., Hanson G., McFadden P., et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993, 82(8):2310-2318.
31. Leber B., Walker I.R., Rodriguez A., McBride J.A., Carter R., Brain M.C. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant 1993, 12(4):405-407.
32. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300(19):1068-1073.
33. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304(25):1529-1533.
34. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
35. Odom L.F., August C.S., Githens J.H., Humbert J.R., Morse H., Peakman D., et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A " graft-versus-leukaemia reaction" in man?. Lancet 1978, 2(8089):537-540.
36. Higano C.S., Brixey M., Bryant E.M., Durnam D.M., Doney K., Sullivan K.M., et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990, 50(1):175-177.
37. Collins R.H., Rogers Z.R., Bennett M., Kumar V., Nikein A., Fay J.W. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992, 10(4):391-395.
38. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108(6):806-814.
39. Apperley J.F., Mauro F.R., Goldman J.M., Gregory W., Arthur C.K., Hows J., et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988, 69(2):239-245.
40. Marmont A.M., Horowitz M.M., Gale R.P., Sobocinski K., Ash R.C., van Bekkum D.W., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78(8):2120-2130.
41. Miller J.S., Weisdorf D.J., Burns L.J., Slungaard A., Wagner J.E., Verneris M.R., et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007, 110(7):2761-2763.
42. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86(5):2041-2050.
43. Dolstra H., Fredrix H., Maas F., Coulie P.G., Brasseur F., Mensink E., et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999, 189(2):301-308.
44. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99(6):1928-1937.
45. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99(10):3530-3539.
46. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabin for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
47. Collins R.H., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15(2):433-444.
48. Porter D.L., Collins R.H., Hardy C., Kernan N.A., Drobyski W.R., Giralt S., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000, 95(4):1214-1221.
49. Dazzi F., Szydlo R.M., Cross N.C., Craddock C., Kaeda J., Kanfer E., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000, 96(8):2712-2716.
50. Shiobara S., Nakao S., Ueda M., Yamazaki H., Takahashi S., Asano S., et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000, 26(7):769-774.
51. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112(12):4371-4383.
52. Choi S.J., Lee J.H., Kim S., Seol M., Lee Y.S., Lee J.S., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004, 18(11):1789-1797.
53. Schmid C., Labopin M., Nagler A., Bornhauser M., Finke J., Fassas A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25(31):4938-4945.
54. Mrsic M., Horowitz M.M., Atkinson K., Biggs J.C., Champlin R.E., Ehninger G., et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992, 9(4):269-275.
55. Radich J.P., Sanders J.E., Buckner C.D., Martin P.J., Petersen F.B., Bensinger W., et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993, 11(2):304-313.
56. Mehta J., Powles R., Treleaven J., Horton C., Meller S., Pinkerton C.R., et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997, 19(7):709-719.
57. Slavin S., Nagler A., Shapira M.Y., Aker M., Gabriel C., Or R. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol 2002, 22(2):64-69.
58. Mortimer J., Blinder M.A., Schulman S., Appelbaum F.R., Buckner C.D., Clift R.A., et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989, 7(1):50-57.
59. Frassoni F., Barrett A.J., Granena A., Ernst P., Garthon G., Kolb H.J., et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988, 70(3):317-320.
60. Bostrom B., Woods W.G., Nesbit M.E., Krivit W., Kersey J., Weisdorf D., et al. Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation. J Clin Oncol 1987, 5(3):376-381.
61. Barrett A.J., Joshi R., Tew C. How should acute lymphoblastic leukaemia relapsing after bone-marrow transplantation be treated?. Lancet 1985, 1(8439):1188-1191.
62. Barrett A.J., Locatelli F., Treleaven J.G., Gratwohl A., Szydlo R., Zwaan F.E. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991, 79(4):567-574.
63. Bosi A., Laszlo D., Labopin M., Reffeirs J., Michallet M., Gluckman E., et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001, 19(16):3675-3684.
64. Choi S.J., Lee J.H., Kim S., Lee Y.S., Seol M., Ryu S.G., et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005, 36(2):163-169.
65. Collins R.H., Goldstein S., Giralt S., Levine J., Porter D., Drobyski W., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000, 26(5):511-516.
66. Dazzi F., Szydlo R.M., Craddock C., Cross N.C., Kaeda J., Chase A., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95(1):67-71.
67. Brouwer R.E., van der Heiden P., Schreuder G.M., Mulder A., Datema G., Anholts J.D., et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002, 63(3):200-210.
68. Ossendorp F., Eggers M., Neisig A., Ruppert T., Groettrup M., Sijts A., et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 1996, 5(2):115-124.
69. Hirano N., Takahashi T., Ohtake S., Hirashima K., Emi N., Saito K., et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996, 10(7):1168-1176.
70. Cardoso A.A., Schultze J.L., Boussiotis V.A., Freeman G.J., Seamon M.J., Laszlo S., et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996, 88(1):41-48.
71. Bergmann L., Schui D.K., Brieger J., Weidmann E., Mitrou P.S., Hoelzer D. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp Hematol 1995, 23(14):1574-1580.
72. Buzyn A., Petit F., Ostankovitch M., Figueiredo S., Varet B., Guillet J.G., et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999, 94(9):3135-3140.
73. Ratanatharathorn V., Uberti J., Karanes C., Abella E., Lum L.G., Momin F., et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994, 84(4):1050-1055.
74. Jones R.J., Ambinder R.F., Piantadosi S., Santos G.W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77(3):649-653.
75. Anderlini P., Acholonu S.A., Okoroji G.J., Andersson B.S., Couriel D.R., De Lima M.J., et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004, 34(6):511-514.
76. Bishop M.R., Dean R.M., Steinberg S.M., Odom J., Pavletic S.Z., Chow C., et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008, 19(11):1935-1940.
77. Bloor A.J., Thomson K., Chowdhry N., Verfuerth S., Ings S.J., Chakraverty R., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14(1):50-58.
78. Peggs K.S., Sureda A., Qian W., Caballero D., Hunter A., Urbano-Ispizua A., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139(1):70-80.
79. Morris E., Thomson K., Craddock C., Mahendra P., Milligan D., Cook G., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104(13):3865-3871.
80. Mandigers C.M., Verdonck L.F., Meijerink J.P., Dekker A.W., Schattenberg A.V., Raemaekers J.M. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32(12):1159-1163.
81. Bierman P.J., Sweetenham J.W., Loberiza F.R., Taghipour G., Lazarus H.M., Rizzo J.D., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation - the lymphoma working committee of the international bone marrow transplant registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21(20):3744-3753.
82. Bjorkstrand B.B., Ljungman P., Svensson H., Hermans J., Alegre A., Apperley J., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88(12):4711-4718.
83. Gahrton G., Tura S., Ljungman P., Blade J., Brandt L., Cavo M., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13(6):1312-1322.
84. Bensinger W.I., Buckner C.D., Anasetti C., Clift R., Storb R., Barnett T., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88(7):2787-2793.
85. Lokhorst H.M., Schattenberg A., Cornelissen J.J., van Oers M.H., Fibbe W., Russell I., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18(16):3031-3037.
86. van de Donk N.W., Kroger N., Hegenbart U., Corradini P., San Miguel J.F., Goldschmidt H., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37(12):1135-1141.
87. Alyea E., Weller E., Schlossman R., Canning C., Webb I., Doss D., et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001, 98(4):934-939.
88. Badros A., Barlogie B., Morris C., Desikan R., Martin S.R., Munshi N., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97(9):2574-2579.
89. Peggs K.S., Banerjee L., Thomson K., Mackinnon S. Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplant 2003, 31(8):725-726. [author reply 7].
90. Marks D.I., Lush R., Cavenagh J., Milligan D.W., Schey S., Parker A., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002, 100(9):3108-3114.
91. Peggs K.S., Mackinnon S., Linch D.C. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005, 128(2):153-168.
92. Carlens S., Remberger M., Aschan J., Ringden O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001, 7(1):31-38.
93. Keil F., Haas O.A., Fritsch G., Kalhs P., Lechner K., Mannhalter C., et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997, 89(9):3113-3117.
94. Ball E.D., Guyre P.M., Mills L., Fisher J., Dinces N.B., Fanger M.W. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32). J Hematother 1992, 1(1):85-94.
95. Willemsen R.A., Debets R., Chames P., Bolhuis R.L. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003, 64(1):56-68.
96. Gall J.M., Davol P.A., Grabert R.C., Deaver M., Lum L.G. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005, 33(4):452-459.
97. Lum L.G., Davol P.A. Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother Biol Response Modif 2005, 22:273-291.
98. Buhmann R., Simoes B., Stanglmaier M., Yang T., Faltin M., Bund D., et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009, 43(5):383-397.
99. Sebastian M., Kiewe P., Schuette W., Brust D., Peschel C., Schneller F., et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM×Anti-CD3): results of a phase 1/2 study. J Immunother 2009, 32(2):195-202.
100. Lafferty K.J., Cunningham A.J. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975, 53(1):27-42.
101. Anderson L.D., Petropoulos D., Everse L.A., Mullen C.A. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Cancer Res 1999, 59(7):1525-1530.
102. Kwak L.W., Pennington R., Longo D.L. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996, 87(7):3053-3060.
103. Kwak L.W., Taub D.D., Duffey P.L., Bensinger W.I., Bryant E.M., Reynolds C.W., et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345(8956):1016-1020.
104. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2(1):52-58.
105. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276(5319):1719-1724.
106. Verzeletti S., Bonini C., Marktel S., Nobili N., Ciceri F., Traversari C., et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998, 9(15):2243-2251.
107. Thomis D.C., Marktel S., Bonini C., Traversari C., Gilman M., Bordignon C., et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001, 97(5):1249-1257.
108. Nimer S.D., Giorgi J., Gajewski J.L., Ku N., Schiller G.J., Lee K., et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994, 57(1):82-87.
109. Schmid C., Schleuning M., Ledderose G., Tischer J., Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23(24):5675-5687.
110. Levenga H., Levison-Keating S., Schattenberg A.V., Dolstra H., Schaap N., Raymakers R.A. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant 2007, 40(4):355-359.